GSK posts $11.28 billion Q2 revenue and launches £1.9 billion savings drive

• GSK reported second-quarter 2026 revenue of $11.28 billion (£8.41 billion), surpassing analyst forecasts of $10.77 billion.
• The pharmaceutical company's adjusted earnings per share reached $1.36, beating the $1.27 consensus estimate.
• GSK shares rose 4.2% in London trading following the announcement of the earnings beat and a new £1.9 billion cost-savings program.

GSK (NYSE:GSK) reported its second-quarter 2026 earnings on July 28, 2026, delivering an adjusted profit of $1.36 per share to top the analyst consensus of $1.27.

The British pharmaceutical giant generated total quarterly revenue of $11.28 billion (£8.41 billion), surpassing Wall Street forecasts of approximately $10.77 billion.

The company also posted a core operating profit of £2.80 billion, outperforming the £2.68 billion consensus.

Following the strong earnings beat and strategic announcements, GSK shares were up 4.2% by late morning trading.

The revenue growth was heavily driven by the Specialty Medicines segment, which saw sales rise 14% to £3.8 billion.

This performance was anchored by a 17% increase in Oncology and a 10% rise in HIV treatments.

The Vaccines segment also delivered solid results, with sales growing 8% to £2.3 billion, led by £0.9 billion from the shingles vaccine Shingrix and strong demand for Meningitis vaccines.

Alongside its financial results, GSK launched a £1.9 billion ($2.52 billion) three-year cost-savings program aimed at simplifying the organization and reallocating capital.

The company also announced a £400 million investment in the UK, which includes funding for a new research and development center in Cambridge.

Looking ahead, GSK reaffirmed its full-year 2026 turnover growth expectations of 3% to 5% and declared a second-quarter dividend of 17 pence per share.